
Adapting Biotech Leadership Across Development and Therapies
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
-
Narrado por:
-
De:
Biotech leaders are asked to do a lot; move fast, manage limited resources, and guide teams through very different stages of development. In this episode of The Emerging Biotech Leader, host Kim Kushner talks with Dr. Benit Maru, Senior Vice President at SSI Strategy, about what it really looks like to lead in that environment.
They cover:
- The contrasts between early and late development leadership, and why those transitions can feel like two different roles
- How scenario planning and structured conversations help teams prepare for uncertainty
- Why documents like the clinical development plan or target product profile should be seen as living tools, not paper exercises
- The similarities and differences in leading across modalities—devices, biologics, and advanced therapies like cell and gene
- The importance of team dynamics, culture, and knowing when to bring in outside expertise
This episode is full of practical takeaways for biotech leaders who want to keep their strategies sound, their teams aligned, and their programs moving forward under pressure.
Todavía no hay opiniones